


Making Cancer History

# **Assessment and Management of Delirium in Pediatric Patients** Page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



<sup>&</sup>lt;sup>1</sup> Perform assessment throughout the nursing shift and document results at the end of the shift

<sup>&</sup>lt;sup>2</sup> If baseline QTc  $\geq$  450 milliseconds, notify provider



Page 2 of 7

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### APPENDIX A: Cornell Assessment of Pediatric Delirium (CAPD) Scale

Never 0	Rarely 1	Sometimes 2	Often 3	Always 4	Score
	l	· · · · · · · · · · · · · · · · · · ·	l '	• • • • • • • • • • • • • • • • • • •	

From "Cornell Assessment of Pediatric Delirium: A valid, rapid, observational tool for screening delirium in the PICU.," by C. Traube, G. Silver, J. Kearney, A. Patel, T.M. Atkinson, M.J. Yoon, . . . B. Greenwald, 2014, *Critical Care Medicine*, 42(3), p 656. doi: 10.1097/CCM.0b013e3182a66b76



Page 3 of 7

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **APPENDIX B: BRAIN MAPS – Common Causes of Delirium**

	Assessment	Evaluation	Recommendations	
В	Bring Oxygen	Evaluate for hypoxemia, low cardiac output, anemia	• Improve oxygenation via O <sub>2</sub> delivery, transfuse PRBCs for anemia	
R	Remove/Reduce Drugs	• Evaluate the continued need for anticholinergics and sedative medications (especially benzodiazepines)	Discontinue if possible	
A	Atmosphere	<ul> <li>Room setup</li> <li>Restraint use</li> <li>Caregiver presence</li> <li>Schedule/routine</li> <li>Use of adaptive equipment and/or communication aids (<i>e.g.</i>, glasses and hearing aids)</li> </ul>	<ul> <li>Promote a familiar environment (toys, plants, photos)</li> <li>Control light and noise in the patient's room</li> <li>Lights on with window shades up during the day</li> <li>Doors and window shades closed with lights, TV and music off while asleep</li> <li>Minimize/avoid restraint use</li> <li>Encourage consistent and familiar caregiver presence; promote parenteral involvement</li> <li>Encourage normal day/night routine</li> <li>Re-orient patient to time and place</li> </ul>	
I	Infection/Mobilization/ Inflammation	Infectious workup	<ul> <li>Treat infection and fever</li> <li>Encourage early mobilization as appropriate</li> <li>Consult child life, PT/OT</li> </ul>	
N M	New Organ Dysfunction and Metabolic Disturbance	<ul> <li>CNS, CV, pulmonary, hepatic, renal, endocrine systems</li> <li>Evaluate with CMP and ABG for hypo/hypernatremia, hypo/hyperkalemia, hypocalcemia, alkalosis/acidosis</li> </ul>	Normalize electrolytes     See Appendix D for emergence agitation and NMDA encephalitis	
A	Awake	<ul> <li>No bedtime routine</li> <li>Sleep wake cycle disturbance</li> </ul>	<ul> <li>Establish day/night cycles</li> <li>Cluster care at night</li> <li>Sleep hygiene – schedule uninterrupted 5-6 hours of night time sleep and age appropriate daytime nap; consider use of ear plugs/muffs and eye mask as appropriate</li> </ul>	
P	Pain	Untreated or undertreated pain     Over-treated (sedated)	<ul><li>Adjust analgesia regimen if appropriate</li><li>Daily review of need for tubes/lines</li></ul>	
S	Sedation	<ul><li> Critically evaluate all benzodiazepine use</li><li> Set sedation target</li></ul>	<ul> <li>Consider weaning or discontinuing benzodiazepines</li> <li>Consider adding dexmedetomidine in patients with appropriate hemodynamics</li> </ul>	

<sup>&</sup>quot;Clinical Team to Bedside to Assess Patient: BRAIN MAPS," by The Children's Hospital of Philadelphia's CICU/PCU/PICU Delirium Clinical Pathway, n.d. Copyright 2019 by Children's Hospital of Philadelphia.



Making Cancer History®

### **Assessment and Management of Delirium in Pediatric Patients**

Page 4 of 7

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **APPENDIX C: Pharmacologic Therapies**<sup>1</sup>

Medication	Starting Dosing	Maximum Daily Dose	Adverse Effects	Monitoring
Chlorpromazine	2.5-6 mg/kg/day divided every 4 to 6 hours PO	Age ≤ 5 years old: 50 mg/day Age > 5 years old: 200 mg/day	<ul> <li>Altered cardiac conduction</li> <li>Anticholinergic effects (dry mouth, blurred vision,</li> </ul>	<ul><li>EKG at baseline and then periodically</li><li>CBC with differential</li></ul>
Haloperidol	Loading dose: 0.15-0.25mg IV  Maintenance dose: 0.05-0.5 mg/kg/day in divided doses IV	0.45 mg/kg/day	constipation, urinary retention)  Blood dyscrasias  Extrapyramidal symptoms  Neuroleptic malignant syndrome  CNS depression  Vital signs  Mental status  Involuntary move extrapyramidal sy	
Olanzapine	4 mg PO daily	10 mg/day	Orthostatic hypotension	
Quetiapine	0.5 mg/kg PO every 8 hours	6 mg/kg/day	• Falls	
Risperidone	Age < 5 years old: 0.1-0.2 mg PO daily at bedtime Age ≥ 5 years old: 0.2-0.5 mg PO daily at bedtime	Weight < 20 kg: 1 mg/day Weight 20-45 kg: 2.5 mg/day Weight > 45 kg: 3 mg/day		
Aripiprazole	2 mg PO daily	15 mg/day	<ul> <li>Altered cardiac conduction</li> <li>Blood dyscrasias</li> <li>Extrapyramidal symptoms</li> <li>Neuroleptic malignant syndrome</li> <li>CNS depression</li> <li>Orthostatic hypotension</li> <li>Falls</li> </ul>	

<sup>&</sup>lt;sup>1</sup> Consider consulting Psychiatry and/or Pediatric Support Care when prescribing these medications



Page 5 of 7

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **APPENDIX D: Additional Differential Diagnostic Considerations**

The diagnosis of delirium may require additional considerations including:					
Emergence Agitation	This is a phenomenon noted in patients who are recovering from anesthesia. This impacts many children after surgery and also occurs in children recovering from anesthesia for non-painful procedures ( <i>e.g.</i> , MRI). Emergence agitation generally resolves once the anesthetic wears off.				
Anti-NMDA Encephalitis Associated Delirium	Anti-NMDA encephalitis is a rare cause of delirium and acute agitation in pediatrics. Diagnosis is made in conjunction with Neurology, Psychiatry and oncology subspecialists based off of CSF studies.  Delirium associated with anti-NMDA encephalitis is treated best in consultation with Psychiatry. Treatment of underlying disorder is required; treatment of delirium has been described utilizing benzodiazepines, clonidine and olanzapine (limited evidence from case report) <sup>1</sup> .				
Non-delirious Disorganized Behavior	Disorganized behavior may manifest in some patients (especially young) in which the diagnosis of delirium is difficult to make. These patients may be delirious. If patient safety and/or dislodgement of high-risk medical devices is of concern, these patients may be treated with a trial of pharmacological therapy after the risks and benefits of these treatments have been discussed with parents/caregivers.  Consult Psychiatry and/or Pediatric Supportive Care				

<sup>&</sup>quot;Additional Differential Diagnostic Considerations" by Children's Hospital of Philadelphia's CICU/PCU/PICU Delirium Clinical Pathway, n.d. Copyright 2019 by Children's Hospital of Philadelphia.

<sup>&</sup>lt;sup>1</sup> Scharko, A. M., Panzer, J., & McIntyre, C. M. (2015). Treatment of delirium in the context of anti–N-methyl-D-aspartate receptor antibody encephalitis. Journal of the American Academy of Child & Adolescent Psychiatry, 54(3), 233-234. doi: 10.1016/j.jaac.2014.12.014



Page 6 of 7

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### SUGGESTED READINGS

- Children's Hospital of Philadelphia. CICU/PCU/PICU Delirium Pathway. Retrieved from https://www.chop.edu/clinical-pathway/picu-pcu-delirium-clinical-pathway
- Joyce, C., Witcher, R., Herrup, E., Kaur, S., Mendez-Rico, E., Silver, G., . . . Traube, C. (2015). Evaluation of the safety of quetiapine in treating delirium in critically ill children: A retrospective review. *Journal of Child and Adolescent Psychopharmacology*, 25(9), 666-670. doi: 10.1089/cap.2015.0093
- Mody, K., Kaur, S., Mauer, E. A., Gerber, L. M., Greenwald, B. M., Silver, G., & Traube, C. (2018). Benzodiazepines and development of delirium in critically ill children: Estimating the causal effect. *Critical Care Medicine*, 46(9), 1486-1491. doi: 10.1097/CCM.000000000003194
- Reade, M. C., Eastwood, G. M., Bellomo, R., Bailey, M., Bersten, A., Cheung, B., . . . Harley, N. (2016). Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: A randomized clinical trial. *JAMA*, 315(14), 1460-1468. doi: 10.1001/jama.2016.2707
- Smith, H. A., Brink, E., Fuchs, D. C., Ely, E. W., & Pandharipande, P. P. (2013). Pediatric delirium: Monitoring and management in the pediatric intensive care unit. *Pediatric Clinics*, 60(3), 741-760. doi: 10.1016/j.pcl.2013.02.010
- Traube, C., Silver, G., Gerber, L. M., Kaur, S., Mauer, E. A., Kerson, A., . . . Greenwald, B. M. (2017). Delirium and mortality in critically ill children: Epidemiology and outcomes of pediatric delirium. *Critical Care Medicine*, 45(5), 891-898. doi: 10.1097/CCM.0000000000002324
- Traube, C., Silver, G., Kearney, J., Patel, A., Atkinson, T. M., Yoon, M. J., . . . Greenwald, B. (2014). Cornell Assessment of Pediatric Delirium: A valid, rapid, observational tool for screening delirium in the PICU. *Critical Care Medicine*, 42(3), 656-663. doi: 10.1097/CCM.0b013e3182a66b76
- Turkel, S. B., Jacobson, J., Munzig, E., & Tavaré, C. J. (2012). Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. *Journal of Child and Adolescent Psychopharmacology*, 22(2), 126-130. doi: 10.1089/cap.2011.0084



Page 7 of 7

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **DEVELOPMENT CREDITS**

This practice consensus statement is based on majority opinion of the Pediatric Delirium workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Patricia Amado, RN (Pediatrics)

Mary Katherine Gardner, RN (Pediatrics)

Joanne Greene, RN (Pediatrics)

Kevin Madden, MD (Palliative Care Medicine)

Rodrigo Mejia, MD (Pediatrics)<sup>\*</sup>

Karen Moody, MD (Pediatrics)

Shehla Razvi, MD (Pediatrics)

Daniel Tan, MD (Psychiatry)

Sonal Yang, PharmD

<sup>&</sup>lt;sup>†</sup>Core Development Lead

<sup>\*</sup>Clinical Effectiveness Development Team